Analysis of translation factors using public database of breast cancer patients.

Breast cancer is originated from cancer stem cells (CSCs). Since CSCs are responsible for the chemoresistance and cancer relapse, it is essential to develop novel therapeutic drugs for the eradication of CSC. We have previously reported that translation factor X is involved in the proliferation of breast CSCs. In the present study, we examined the role of translation factor X in the xenograft experiments and clinical samples. First, we examined the effect of translation factor X on tumorigenicity in nude mice. Overexpression of factor X increased tumorigenicity of breast CSCs. Next, we analyzed the expression levels of translation factor X using clinical samples from patient with breast cancer. By analyzing RNA-seq data of breast cancer patients from the National Center for Biotechnology Information, translation factor X was highly expressed in breast cancer tissue samples, compared with normal tissue and early neoplasia. Finally, we analyzed cumulative survival analysis from The Cancer Genome Atlas. Kaplan-Meier analysis showed that mRNA level of translation factor X was reversely correlated with the overall survival time in patients with breast cancer. These results suggest the translation factor X can be used to predict breast cancer outcomes.